Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 2,6 Dichlorobenzylideneaminoguanidine
2. 2,6-dichlorobenzylideneaminoguanidine
3. Acetate Wyeth-ayerst, Guanabenz
4. Acetate, Guanabenz
5. Br 750
6. Br-750
7. Br750
8. Guanabenz
9. Guanabenz Acetate
10. Guanabenz Acetate Wyeth-ayerst
11. Guanabenz Monoacetate
12. Monoacetate, Guanabenz
13. Wy 8678
14. Wy-8678
15. Wy8678
16. Wyeth Ayerst Of Guanabenz Acetate
17. Wyeth-ayerst Of Guanabenz Acetate
18. Wytensin
1. Guanabenz
2. 5051-62-7
3. Hydrazinecarboximidamide, 2-[(2,6-dichlorophenyl)methylene]-, (e)-
4. Dsstox_cid_25666
5. Dsstox_rid_81042
6. Dsstox_gsid_45666
7. Cas-5051-62-7
8. Ncgc00024846-03
9. Spectrum_000843
10. Prestwick0_000096
11. Prestwick1_000096
12. Spectrum2_001114
13. Spectrum3_000445
14. Spectrum4_000567
15. Kbiogr_000974
16. Kbioss_001323
17. Divk1c_000010
18. Spbio_001248
19. Spbio_001991
20. Chembl1313657
21. Dtxsid6045666
22. Kbio1_000010
23. Kbio2_001323
24. Kbio2_003891
25. Kbio2_006459
26. Kbio3_001310
27. Ninds_000010
28. Hms2233d12
29. Hms3370a17
30. Bcp30851
31. Tox21_110932
32. Akos017264577
33. Tox21_110932_1
34. Zinc242701441
35. Db00629
36. 2,6-dichlorobenzaldehyde Guanylhydrazone
37. Mrf-0000008
38. Ncgc00024846-08
39. Db-051784
40. Ft-0635524
41. Guanabenzum;wy-8678; Wy 8678; Wy8678
42. N-(2,6-dichlorobenzylidene)-n'-amidino Hydrazine
43. Sr-01000721838
44. Sr-01000721838-5
45. Q27164730
| Molecular Weight | 231.08 g/mol |
|---|---|
| Molecular Formula | C8H8Cl2N4 |
| XLogP3 | 1.7 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 2 |
| Exact Mass | 230.0126017 g/mol |
| Monoisotopic Mass | 230.0126017 g/mol |
| Topological Polar Surface Area | 76.8 Ų |
| Heavy Atom Count | 14 |
| Formal Charge | 0 |
| Complexity | 228 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 1 |
| Covalently Bonded Unit Count | 1 |
For management of High blood pressure
FDA Label
Guanabenz, a centrally acting α-2 adrenergic agonist, is indicated for treatment of hypertension.
Adrenergic alpha-2 Receptor Agonists
Compounds that bind to and activate ADRENERGIC ALPHA-2 RECEPTORS. (See all compounds classified as Adrenergic alpha-2 Receptor Agonists.)
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
Absorption
Approximately 75% absorbed from gastrointestinal tract
Hepatic
6 hours.
Guanabenz's antihypertensive effect is thought to be due to central alpha-adrenergic stimulation, which results in a decreased sympathetic outflow to the heart, kidneys, and peripheral vasculature in addition to a decreased systolic and diastolic blood pressure and a slight slowing of pulse rate. Chronic administration of guanabenz also causes a decrease in peripheral vascular resistance.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 14072
Submission : 1999-04-07
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Registrant Name : Rocket Korea Co., Ltd.
Registration Date : 2024-08-28
Registration Number : 20240828-211-J-1682
Manufacturer Name : ROQUETTE FRERES
Manufacturer Address : 1 Rue de la Haute Loge, 62136 LESTREM, France

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]About the Company : FandaChem, headquartered in Hangzhou, China, is a reputable supplier and exporter of chemicals with a focus on delivering high-quality products. Our expertise lies in exporting a w...

About the Company : Hainan Yew Pharmaceutical Co., Ltd was established in April 2009 by its parent company, Fujian Sansan Pharmaceutical Co. Ltd, with an investment of 20 million yuan, including res...

About the Company : Haorui, established in 1997, is a manufacturer and supplier of APIs, intermediates, veterinary and food additives. Meanwhile, it is assisting global pharmaceutical companies to get...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
DSR 2.0 is a disease-modifying heart failure drug therapy, which is currently being evaluated for the treatment of patients with diuretic-resistant heart failure.
Lead Product(s): Icodextrin,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 25, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Icodextrin,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Sequana Medical Confirms Dramatic Diuretic Response Improvement in MOJAVE Cohort Follow-Up
Details : DSR 2.0 is a disease-modifying heart failure drug therapy, which is currently being evaluated for the treatment of patients with diuretic-resistant heart failure.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 25, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
DSR 2.0 (Direct Sodium Removal) via peritoneal ultrafiltration using Infusate 2.0, is under phase 1/2 clinical trials for treatment of patients with diuretic-resistant heart failure.
Lead Product(s): Icodextrin,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 22, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Icodextrin,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Sequana Medical Announces DSMB Approval to Start MOJAVE Phase 1/2a Study of DSR® 2.0
Details : DSR 2.0 (Direct Sodium Removal) via peritoneal ultrafiltration using Infusate 2.0, is under phase 1/2 clinical trials for treatment of patients with diuretic-resistant heart failure.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 22, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
DSR 2.0 (icodextrin, dextrose, dapagliflozin) is an implant small molecule drug combination, currently being investigated for heart failure management.
Lead Product(s): Icodextrin,Dapagliflozin,Dextrose
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 29, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Icodextrin,Dapagliflozin,Dextrose
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DSR 2.0 (icodextrin, dextrose, dapagliflozin) is an implant small molecule drug combination, currently being investigated for heart failure management.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 29, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
DSR 2.0 therapy (icodextrin) involves the use of the peritoneal cavity for the removal of sodium via diffusion. The body responds by eliminating the associated fluid via osmotic ultrafiltration or urination. It is being investigated for congestive heart failure.
Lead Product(s): Icodextrin,Dextrose
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 18, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Icodextrin,Dextrose
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Sequana Medical Announces Initial Positive Data from MOJAVE, a US Phase 1/2a study of DSR® 2.0 fo...
Details : DSR 2.0 therapy (icodextrin) involves the use of the peritoneal cavity for the removal of sodium via diffusion. The body responds by eliminating the associated fluid via osmotic ultrafiltration or urination. It is being investigated for congestive heart ...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 18, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Icodextrin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Heart Failure.
Lead Product(s): Icodextrin,Dapagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 28, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Icodextrin,Dapagliflozin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Icodextrin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Heart Failure.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 28, 2023

Details:
Icodextrin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Renal Insufficiency, Chronic.
Lead Product(s): Icodextrin,Dextrose
Therapeutic Area: Nephrology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Sequana Medical
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 22, 2023

Lead Product(s) : Icodextrin,Dextrose
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Sequana Medical
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety of and Tolerability to a Sodium-free Peritoneal Dialysis Solution
Details : Icodextrin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Renal Insufficiency, Chronic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 22, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
DSR 2.0 therapy involves the use of the peritoneal cavity for the removal of sodium via diffusion. The body responds by eliminating the associated fluid via osmotic ultrafiltration or urination. It is being investigated for congestive heart failure.
Lead Product(s): Icodextrin,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 01, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Icodextrin,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DSR 2.0 therapy involves the use of the peritoneal cavity for the removal of sodium via diffusion. The body responds by eliminating the associated fluid via osmotic ultrafiltration or urination. It is being investigated for congestive heart failure.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 01, 2023

Details:
Icodextrin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Lead Product(s): Icodextrin,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Baxter Healthcare Corporation
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 10, 2023

Lead Product(s) : Icodextrin,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Baxter Healthcare Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Icodextrin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 10, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Icodextrin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Kidney Failure, Chronic.
Lead Product(s): Icodextrin,Ribitol,Levocarnitine
Therapeutic Area: Nephrology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 11, 2019

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Icodextrin,Ribitol,Levocarnitine
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Ultrafiltration Efficacy of a PD Solution Containing Icodextrin-Xylitol-Carnitine
Details : Icodextrin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Kidney Failure, Chronic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 11, 2019

Details:
Icodextrin is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Kidney Failure, Chronic.
Lead Product(s): Icodextrin,Inapplicable
Therapeutic Area: Nephrology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Miscellaneous
Sponsor: Baxter Healthcare Corporation
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 18, 2014

Lead Product(s) : Icodextrin,Inapplicable
Therapeutic Area : Nephrology
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Baxter Healthcare Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Extraneal (Icodextrin) on Triglyceride Levels in PD Patients
Details : Icodextrin is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Kidney Failure, Chronic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 18, 2014

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Market Place
ABOUT THIS PAGE
49
PharmaCompass offers a list of Icodextrin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Icodextrin manufacturer or Icodextrin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Icodextrin manufacturer or Icodextrin supplier.
A Extraneal manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Extraneal, including repackagers and relabelers. The FDA regulates Extraneal manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Extraneal API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Extraneal manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Extraneal supplier is an individual or a company that provides Extraneal active pharmaceutical ingredient (API) or Extraneal finished formulations upon request. The Extraneal suppliers may include Extraneal API manufacturers, exporters, distributors and traders.
click here to find a list of Extraneal suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Extraneal DMF (Drug Master File) is a document detailing the whole manufacturing process of Extraneal active pharmaceutical ingredient (API) in detail. Different forms of Extraneal DMFs exist exist since differing nations have different regulations, such as Extraneal USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Extraneal DMF submitted to regulatory agencies in the US is known as a USDMF. Extraneal USDMF includes data on Extraneal's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Extraneal USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Extraneal suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Extraneal Drug Master File in Korea (Extraneal KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Extraneal. The MFDS reviews the Extraneal KDMF as part of the drug registration process and uses the information provided in the Extraneal KDMF to evaluate the safety and efficacy of the drug.
After submitting a Extraneal KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Extraneal API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Extraneal suppliers with KDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Extraneal as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Extraneal API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Extraneal as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Extraneal and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Extraneal NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Extraneal suppliers with NDC on PharmaCompass.
Extraneal Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Extraneal GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Extraneal GMP manufacturer or Extraneal GMP API supplier for your needs.
A Extraneal CoA (Certificate of Analysis) is a formal document that attests to Extraneal's compliance with Extraneal specifications and serves as a tool for batch-level quality control.
Extraneal CoA mostly includes findings from lab analyses of a specific batch. For each Extraneal CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Extraneal may be tested according to a variety of international standards, such as European Pharmacopoeia (Extraneal EP), Extraneal JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Extraneal USP).